Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-14 (cancelled).

~~Claims~~

What is claimed is:

15. (New) A compound of formula (I) or a pharmaceutically acceptable derivative thereof:



(I)

wherein:

one of Z^1, Z^2, Z^3, Z^4 and Z^5 is N, one is CR^{1a} and the remainder are CH, or one of Z^1, Z^2, Z^3, Z^4 and Z^5 is CR^{1a} and the remainder are CH;

R^1 and R^{1a} are independently selected from hydrogen; hydroxy; (C_{1-6}) alkoxy optionally substituted by (C_{1-6})alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups, CONH2, hydroxy, (C_{1-6})alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6})alkylsulphonyloxy; (C_{1-6})alkoxy-substituted (C_{1-6})alkyl; halogen; (C_{1-6})alkyl; (C_{1-6})alkylthio; trifluromethyl; nitro; azido; acyl; acyloxy; acylthio; (C_{1-6})alkylsulphonyl; (C_{1-6})alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups, or when Z^1 is CR^{1a}, R^1 and R^{1a} may together represent (C_{1-2})alkylenedioxy, or when Z^5 is CR^{1a}, R^{1a} may instead be, cyano, hydroxymethyl or carboxy,
provided that when Z^1, Z^2, Z^3, Z^4 and Z^5 are CR^{1a} or CH, then R^1 is not hydrogen;

R^2 is hydrogen, or (C_{1-4})alkyl or (C_{2-4})alkenyl optionally substituted with 1 to 3 groups selected from:
amino optionally substituted by one or two (C_{1-4})alkyl groups; carboxy; (C_{1-4})alkoxycarbonyl; (C_{1-4})alkylcarbonyl; (C_{2-4})alkenyloxycarbonyl; (C_{2-4})alkenylcarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C_{1-4})alkyl, hydroxy(C_{1-4})alkyl, aminocarbonyl(C_{1-4})alkyl, (C_{2-4})alkenyl, (C_{1-4})alkylsulphonyl, trifluoromethylsulphonyl, (C_{2-4})alkenylsulphonyl, (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl or (C_{2-4})alkenylcarbonyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R^{10}; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R^{10}; 5-oxo-1,2,4-oxadiazol-3-yl; halogen; (C_{1-4})alkylthio; trifluoromethyl; hydroxy optionally substituted by (C_{1-4})alkyl, (C_{2-4})alkenyl, (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl; oxo; (C_{1-4})alkylsulphonyl; (C_{2-4})alkenylsulphonyl; or (C_{1-4})aminosulphonyl wherein the amino group is optionally substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl;
R^3 ishydroxy optionally substituted by (C_{1-6})alkyl, (C_{2-6})alkenyl, (C_{1-6})alkoxycarbonyl, (C_{1-6})alkylcarbonyl, (C_{2-6})alkenyloxycarbonyl, (C_{2-6})alkenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (C_{1-6})alkyl, (C_{2-6})alkenyl, (C_{1-6})alkylcarbonyl or (C_{2-6})alkenylcarbonyl;
R^{10} is selected from (C_{1-4})alkyl and (C_{2-4})alkenyl either of which may be optionally substituted by a group R^{12} as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C_{1-6})alkyl, (C_{2-6})alkenyl, (C_{1-6})alkylsulphonyl, trifluoromethylsulphonyl, (C_{2-6})alkenylsulphonyl, (C_{1-6})alkoxycarbonyl, (C_{1-6})alkylcarbonyl, (C_{2-6})alkenyloxycarbonyl or (C_{2-6})alkenylcarbonyl and optionally further substituted by (C_{1-6})alkyl or (C_{2-6})alkenyl; (C_{1-6})alkylsulphonyl; trifluoromethylsulphonyl; (C_{2-6})alkenylsulphonyl; (C_{1-6})alkoxycarbonyl; (C_{1-6})alkylcarbonyl; (C_{2-6})alkenyloxycarbonyl; and (C_{2-6})alkenylcarbonyl;
R^4 is a group $-CH_2-R^5{}_1$ in which $R^5{}_1$ is selected from:
(C_{4-8})alkyl; hydroxy(C_{4-8})alkyl; (C_{1-4})alkoxy(C_{4-8})alkyl; (C_{1-4})alkanoyloxy(C_{4-8})alkyl; (C_{3-8})cycloalkyl(C_{4-8})alkyl; hydroxy-, (C_{1-6})alkoxy- or (C_{1-6})alkanoyloxy-(C_{3-8})cycloalkyl(C_{4-8})alkyl; cyano(C_{4-8})alkyl; (C_{4-8})alkenyl; (C_{4-8})alkynyl; tetrahydrofuryl; mono- or di-(C_{1-6})alkylamino(C_{4-8})alkyl; acylamino(C_{4-8})alkyl; (C_{1-6})alkyl- or acyl-aminocarbonyl(C_{4-8})alkyl; mono- or di- (C_{1-6})alkylamino(hydroxy) (C_{4-8})alkyl; or

R^4 is a group $-U-R^5{}_2$ where $R^5{}_2$ is an optionally substituted bicyclic carbocyclic or heterocyclic ring system (A):



(A)

containing up to four heteroatoms in each ring in which

at least one of rings (a) and (b) is aromatic;

X^1 is C or N when part of an aromatic ring or CR^{14} when part of a non aromatic ring;

X^2 is N, NR^{13}, O, $S(O)_x$, CO or CR^{14} when part of an aromatic or non-aromatic ring or may in addition be $CR^{14}R^{15}$ when part of a non aromatic ring;

X^3 and X^5 are independently N or C;

Y^1 is a 0 to 4 atom linker group each atom of which is independently selected from N, NR^{13}, O, $S(O)_x$, CO and CR^{14} when part of an aromatic or non-aromatic ring or may additionally be $CR^{14}R^{15}$ when part of a non aromatic ring,

Y^2 is a 2 to 6 atom linker group, each atom of Y^2 being independently selected from N, NR^{13}, O, $S(O)_x$, CO and CR^{14} when part of an aromatic or non-aromatic ring or may additionally be $CR^{14}R^{15}$ when part of a non aromatic ring;

each of R^{14} and R^{15} is independently selected from: H; (C_{1-4})alkylthio; halo; carboxy(C_{1-4})alkyl; halo(C_{1-4})alkoxy; halo(C_{1-4})alkyl; (C_{1-4})alkyl; (C_{2-4})alkenyl; (C_{1-4})alkoxycarbonyl; formyl; (C_{1-4})alkylcarbonyl; (C_{2-4})alkenyloxycarbonyl; (C_{2-4})alkenylcarbonyl; (C_{1-4})alkylcarbonyloxy; (C_{1-4})alkoxycarbonyl(C_{1-4})alkyl; hydroxy; hydroxy(C_{1-4})alkyl; mercapto(C_{1-4})alkyl; (C_{1-4})alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted as for corresponding substituents in R^3; (C_{1-4})alkylsulphonyl; (C_{2-4})alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; aryl; aryl(C_{1-4})alkyl; aryl(C_{1-4})alkoxy;

each R^{13} is independently H; trifluoromethyl; (C_{1-4})alkyl optionally substituted by hydroxy, carboxy, (C_{1-6})alkoxycarbonyl, (C_{1-6})alkoxy, (C_{1-6})alkylthio, halo or trifluoromethyl; (C_{2-4})alkenyl; aryl; aryl (C_{1-4})alkyl; arylcarbonyl; heteroarylcarbonyl; (C_{1-4})alkoxycarbonyl; (C_{1-4})alkylcarbonyl; formyl; (C_{1-6})alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl, (C_{1-4})alkyl or (C_{2-4})alkenyl and optionally further substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl;

each x is independently 0, 1 or 2;

U is CO, SO_2 or CH_2; or

R^4 is a group $-X^{1a}-X^{2a}-X^{3a}-X^{4a}$ in which:

X^{1a} is CH_2, CO or SO_2;

X^{2a} is $CR^{14a}R^{15a}$;

X^{3a} is NR^{13a}, O, S, SO_2 or $CR^{14a}R^{15a}$; wherein:

each of R^{14a} and R^{15a} is independently selected from the groups listed above for R^{14} and R^{15}, provided that R^{14a} and R^{15a} on the same carbon atom are not both selected from optionally substituted hydroxy and optionally substituted amino; or

R^{14a} and R^{15a} together represent oxo;

R^{13a} is hydrogen; trifluoromethyl; (C_{1-6})alkyl; (C_{2-6})alkenyl; (C_{1-6})alkoxycarbonyl; (C_{1-6})alkylcarbonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C_{1-6})alkoxycarbonyl, (C_{1-6})alkylcarbonyl, (C_{2-6})alkenyloxycarbonyl, (C_{2-6})alkenylcarbonyl, (C_{1-6})alkyl or (C_{2-6})alkenyl and optionally further substituted by (C_{1-6})alkyl or (C_{2-6})alkenyl; or

two R^{14a} groups or an R^{13a} and an R^{14a} group on adjacent atoms together represent a bond and the remaining R^{13a}, R^{14a} and R^{15a} groups are as above defined; or

two R^{14a} groups and two R^{15a} groups on adjacent atoms together represent bonds such that X^{2a} and X^{3a} is triple bonded;

X^{4a} is phenyl or C or N linked monocyclic aromatic 5- or 6-membered heterocycle containing up to four heteroatoms selected from O, S and N and: optionally C-substituted by up to three groups selected from (C_{1-4})alkylthio; halo; carboxy(C_{1-4})alkyl; halo(C_{1-4})alkoxy; halo(C_{1-4})alkyl; (C_{1-4})alkyl; (C_{2-4})alkenyl; (C_{1-4})alkoxycarbonyl; formyl; (C_{1-4})alkylcarbonyl; (C_{2-4})alkenyloxycarbonyl; (C_{2-4})alkenylcarbonyl; (C_{1-4})alkylcarbonyloxy; (C_{1-4})alkoxycarbonyl(C_{1-4})alkyl; hydroxy; hydroxy(C_{1-4})alkyl; mercapto(C_{1-4})alkyl; (C_{1-4})alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted as for corresponding substituents in R^3; (C_{1-4})alkylsulphonyl; (C_{2-4})alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; aryl, aryl(C_{1-4})alkyl or aryl(C_{1-4})alkoxy; and

optionally N substituted by trifluoromethyl; (C_{1-4})alkyl optionally substituted by hydroxy, (C_{1-6})alkoxy, (C_{1-6})alkylthio, halo or trifluoromethyl; (C_{2-4})alkenyl; aryl; aryl(C_{1-4})alkyl; (C_{1-4})alkoxycarbonyl; (C_{1-4})alkylcarbonyl; formyl; (C_{1-6})alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl, (C_{1-4})alkyl or (C_{2-4})alkenyl and optionally further substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl;

n is 0 or 1 and AB is $NR^{11}CO$, $CONR^{11}$, $CO\text{-}CR^8R^9$, $CR^6R^7\text{-}CO$, $O\text{-}CR^8R^9$, $CR^6R^7\text{-}O$, $NHR^{11}\text{-}CR^8R^9$, $CR^6R^7\text{-}NHR^{11}$, $NR^{11}SO_2$, $CR^6R^7\text{-}SO_2$ or $CR^6R^7\text{-}CR^8R^9$,
provided that n=0, B is not NR^{11} , O or SO_2,
and provided that R^6 and R^7, and R^8 and R^9 are not both optionally substituted hydroxy or amino;
and wherein:
each of R^6, R^7 , R^8 and R^9 is independently selected from: H; (C_{1-6})alkoxy; (C_{1-6})alkylthio; halo; trifluoromethyl; azido; (C_{1-6})alkyl; (C_{2-6})alkenyl; (C_{1-6})alkoxycarbonyl; (C_{1-6})alkylcarbonyl; (C_{2-6})alkenyloxycarbonyl; (C_{2-6})alkenylcarbonyl; hydroxy, amino or aminocarbonyl optionally substituted as for corresponding substituents in R^3; (C_{1-6})alkylsulphonyl; (C_{2-6})alkenylsulphonyl; or (C_{1-6})aminosulphonyl wherein the amino group is optionally substituted by (C_{1-6})alkyl or (C_{2-6})alkenyl;
or R^6 and R^8 together represent a bond and R^7 and R^9 are as above defined;
in optionally substituted amino the amino group is optionally mono- or disubstituted by (C_{1-6})alkoxycarbonyl, (C_{1-6})alkylcarbonyl, (C_{2-6})alkenyloxycarbonyl, (C_{2-6})alkenylcarbonyl, (C_{1-6})alkyl, (C_{2-6})alkenyl, (C_{1-6})alkylsulphonyl, (C_{2-6})alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (C_{1-6})alkyl or (C_{2-6})alkenyl;
in optionally substituted aminocarbonyl the amino group is optionally substituted by (C_{1-6})alkyl, hydroxy(C_{1-6})alkyl, aminocarbonyl(C_{1-6})alkyl, (C_{2-6})alkenyl, (C_{1-6})alkoxycarbonyl, (C_{1-6})alkylcarbonyl, (C_{2-6})alkenyloxycarbonyl or (C_{2-6})alkenylcarbonyl and optionally further substituted by (C_{1-6})alkyl, hydroxy(C_{1-6})alkyl, aminocarbonyl(C_{1-6})alkyl or (C_{2-6})alkenyl;
and each R^{11} is independently H; trifluoromethyl; (C_{1-6})alkyl; (C_{2-6})alkenyl; (C_{1-6})alkoxycarbonyl; (C_{1-6})alkylcarbonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C_{1-6})alkoxycarbonyl, (C_{1-6})alkylcarbonyl, (C_{2-6})alkenyloxycarbonyl, (C_{2-6})alkenylcarbonyl, (C_{1-6})alkyl or (C_{2-6})alkenyl and optionally further substituted by (C_{1-6})alkyl or (C_{2-6})alkenyl;
or where one of R^6, R^7, R^8 or R^9 contains a carboxy group they may together with R^3 form a cyclic ester linkage.

16. (New) A compound according to claim 15 wherein Z^5 is CH, Z^3 is CH or CF, Z^1 is CH or C-OCH_3 and Z^2 and Z^4 are each CH, or Z^1 is N, Z^3 is CH or CF and Z^2, Z^4 and Z^5 are each CH

17. (New) A compound according to claim 15 wherein R^1 is methoxy or fluoro and R^{1a} is H or when Z^3 is CR^{1a} it may be C-F.

18. (New) A compound according to claim 15 wherein R^2 is hydrogen.

19. (New) A compound according to claim 15 wherein R^3 is hydroxy.

20. (New) A compound according to claim 15 wherein n is 0 and either A is CHOH or CH_2 and B is CH_2 or A is NH and B is CO, and $AB(CH_2)_n$ and NR^2R^4 are trans.

21. (New) A compound according to claim 15 wherein R^4 is $-U-R^5{}_2$, the group –U– is $-CH_2-$, and $R^5{}_2$ is an aromatic heterocyclic ring (A) having 8-11 ring atoms including 2-4 heteroatoms of which at least one is N or NR^{13} or the heterocyclic ring (A) has ring (a) aromatic selected from optionally substituted benzo and pyrido and ring (b) non-aromatic and Y^2 has 3-5 atoms including NR^{13}, O or S bonded to X^5 and NHCO bonded via N to X^3, or O bonded to X^3.

22. (New) A compound according to claim 15 wherein $R^5{}_2$ is selected from:benzo[1,2,5]thiadiazol-5-yl
4H-benzo[1,4] thiazin-3-one-6-yl
2,3-dihydro-benzo[1,4]dioxin-6-yl
benzo[1,2,3]thiadiazol-5-yl
3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl
7-fluoro-3-oxo-3,4-dihydro-2H-benzo[1,4] oxazin-6-yl
2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]thiazin-7-yl
2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl
3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl
[1,2,3]thiadiazolo[5,4-b]pyridin-6-yl
3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazin-6-yl
7-chloro-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazin-6-yl
7-fluoro-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazin-6-yl
2-oxo-2,3-dihydro-1*H*-pyrido[3,4-*b*][1,4]thiazin-7-yl.

23. (New) A compound selected from:
(1*R*,4*S*)-1-Hydroxy-4-[(3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazin-6-ylmethyl)-amino]-cyclohex-2-enecarboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide and
(1*S*,4*R*)-1-Hydroxy-4-[(3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazin-6-ylmethyl)-amino]-cyclohex-2-enecarboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide

(1*R*,4*S*)-1-Hydroxy-4-[(3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]oxazin-6-ylmethyl)-amino]-cyclohex-2-enecarboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide and (1*S*,4*R*)-1-Hydroxy-4-[(3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]oxazin-6-ylmethyl)-amino]-cyclohex-2-enecarboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide 1-Hydroxy-*t*-4-[(2,3-dihydro[1,4]dioxino[2,3-*c*]pyridine-7-ylmethyl)-amino]-*r*-cyclohex-2-enecarboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide (E2 isomer) or a pharmaceutically acceptable derivative thereof.

24. (New) A method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound according to claim 15.

25. (New) A pharmaceutical composition comprising a compound according to claim 15, and a pharmaceutically acceptable carrier.

26. (New) A process for preparing a compound according to claim 15, which process comprises reacting a compound of formula (IV) with a compound of formula (V):



(IV)



(V)

wherein n is as defined in formula (I); $Z^{1'}$, $Z^{2'}$, $Z^{3'}$, $Z^{4'}$, $Z^{5'}$, $R^{1'}$ and $R^{3'}$ are Z^1, Z^2, Z^3, Z^4, Z^5, R^1 and R^3 as defined in formula (I) or groups convertible thereto;
Q^1 is $NR^{2'}R^{4'}$ or a group convertible thereto wherein $R^{2'}$ and $R^{4'}$ are R^2 and R^4 as defined in formula (I) or groups convertible thereto and Q^2 is H or $R^{3'}$ or Q^1 and Q^2 together form an optionally protected oxo group;
and X and Y may be the following combinations:

(i) one of X and Y is CO_2R^y and the other is $CH_2CO_2R^x$;
(ii) X is CHR^6R^7 and Y is $C(=O)R^9$;
(iii) X is $CR^7=PR^z{}_3$ and Y is $C(=O)R^9$;
(iv) X is $C(=O)R^7$ and Y is $CR^9=PR^z{}_3$;
(v) one of Y and X is COW and the other is $NHR^{11'}$;
(vi) X is $NHR^{11'}$ and Y is $C(=O)R^8$ or X is $C(=O)R^6$ and Y is $NHR^{11'}$;
(vii) X is $NHR^{11'}$ and Y is CR^8R^9W;
(viii) X is W or OH and Y is CH_2OH;
(ix) X is $NHR^{11'}$ and Y is SO_2W;

(x) one of X and Y is $(CH_2)_p$-W and the other is $(CH_2)_qNHR^{11'}$, $(CH_2)_qOH$, $(CH_2)_qSH$ or $(CH_2)_qSCOR^x$ where p+q=1;

(xi) one of X and Y is OH and the other is $-CH=N_2$;

(xii) Xis W and Y is $CONHR^{11}$;

(xiii) X is W and Y is -C≡CH followed by selective reduction of the intermediate –C≡C- group;

in which W is a leaving group, e.g. halo or imidazolyl; R^x and R^y are (C_{1-6})alkyl; R^z is aryl or (C_{1-6})alkyl; A' and $NR^{11'}$ are A and NR^{11} as defined in formula (I), or groups convertible thereto; and oxirane is:



wherein R^6, R^8 and R^9 are as defined in formula (I);

and thereafter optionally or as necessary converting Q^1 and Q^2 to $NR^{2'}R^{4'}$; converting A', $Z^{1'}$, $Z^{2'}$, $Z^{3'}$, $Z^{4'}$, $Z^{5'}$, $R^{1'}$, $R^{2'}$, $R^{3'}$, $R^{4'}$ and $NR^{11'}$ to A, Z^1, Z^2, Z^3, Z^4, Z^5, R^1, R^2, R^3, R^4 and $NR^{11'}$; converting A-B to other A-B, interconverting R^v, R^w, R^1, R^2, R^3 and/or R^4, and/or forming a pharmaceutically acceptable derivative thereof.

27. (New) A compound of formula (VII):



wherein the variables are as described for formula (I) in claim 15.